TWI256953B - Pyrimidine compounds - Google Patents

Pyrimidine compounds

Info

Publication number
TWI256953B
TWI256953B TW091134807A TW91134807A TWI256953B TW I256953 B TWI256953 B TW I256953B TW 091134807 A TW091134807 A TW 091134807A TW 91134807 A TW91134807 A TW 91134807A TW I256953 B TWI256953 B TW I256953B
Authority
TW
Taiwan
Prior art keywords
nrcrd
orc
nrc
src
heteroaryl
Prior art date
Application number
TW091134807A
Other languages
English (en)
Other versions
TW200400190A (en
Inventor
Mitsunori Ono
Lijun Sun
Teresa Przewloka
Shijie Zhang
Elena Kostik
Original Assignee
Synta Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/000,742 external-priority patent/US6693097B2/en
Application filed by Synta Pharmaceuticals Corp filed Critical Synta Pharmaceuticals Corp
Publication of TW200400190A publication Critical patent/TW200400190A/zh
Application granted granted Critical
Publication of TWI256953B publication Critical patent/TWI256953B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW091134807A 2001-11-30 2002-11-29 Pyrimidine compounds TWI256953B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/000,742 US6693097B2 (en) 2001-11-30 2001-11-30 Pyrimidine compounds
US10/192,347 US6660733B2 (en) 2001-11-30 2002-07-10 2,4,6-trisubstituted-pyrimidine compounds

Publications (2)

Publication Number Publication Date
TW200400190A TW200400190A (en) 2004-01-01
TWI256953B true TWI256953B (en) 2006-06-21

Family

ID=26668093

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091134807A TWI256953B (en) 2001-11-30 2002-11-29 Pyrimidine compounds

Country Status (16)

Country Link
US (2) US6958332B2 (zh)
EP (1) EP1458687B1 (zh)
JP (1) JP2005519034A (zh)
KR (1) KR100950122B1 (zh)
CN (1) CN100349876C (zh)
AU (1) AU2002357033B2 (zh)
BR (1) BR0214809A (zh)
CA (1) CA2468349A1 (zh)
IL (1) IL162189A0 (zh)
IS (1) IS7287A (zh)
MX (1) MXPA04005181A (zh)
NO (1) NO328144B1 (zh)
NZ (1) NZ533437A (zh)
RU (1) RU2320658C2 (zh)
TW (1) TWI256953B (zh)
WO (1) WO2003047516A2 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162189A0 (en) * 2001-11-30 2005-11-20 Synta Pharmaceuticals Corp Pyrimidine compounds
US6693097B2 (en) * 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
EP1556140A4 (en) * 2002-10-15 2006-04-19 Synta Pharmaceuticals Corp NEW COMPOUNDS
CA2545340A1 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
WO2005046619A2 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Compositions and methods for modulating c-rel-dependent cytokine production
CA2545259A1 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Heteroaryl-hydrazone compounds
US7338951B2 (en) * 2003-11-10 2008-03-04 Synta Pharmaceuticals Corp. Pyridine compounds
CA2563895C (en) * 2004-04-13 2012-10-16 Synta Pharmaceuticals Corp. Disalt inhibitors of il-12 production
AU2005262322B2 (en) * 2004-07-01 2012-07-26 Synta Pharmaceuticals Corp. 2-substituted heteroaryl compounds
AU2005284904A1 (en) 2004-09-13 2006-03-23 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP2008519850A (ja) * 2004-11-10 2008-06-12 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２調節化合物
WO2006053109A1 (en) * 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
TW200630363A (en) * 2004-11-10 2006-09-01 Synta Pharmaceuticals Corp Process for preparing trisubstituted pyrimidine compounds
US7851466B2 (en) 2004-11-19 2010-12-14 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
WO2006128172A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
TW200804307A (en) * 2005-10-27 2008-01-16 Synta Pharmaceuticals Corp Process for preparing mesylate salts of IL-12 inhibitory compounds
JP2009518364A (ja) * 2005-12-08 2009-05-07 ラボラトワール セローノ ソシエテ アノニム 増殖を抑えるピリミジル、縮合ピリミジル、ピリジルヒドラゾン
US20080221103A1 (en) * 2007-03-09 2008-09-11 Orchid Research Laboratories Ltd. New heterocyclic compounds
WO2009100406A2 (en) * 2008-02-07 2009-08-13 Synta Pharmaceuticals Corp. Topical formulations for the treatment of psoriasis
EP2254869B1 (en) 2008-03-07 2017-05-31 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Neue 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of cx3cr1 und p40
LT2262778T (lt) 2008-03-07 2019-11-11 Acraf 1-benzil-3-hidroksimetilindazolo dariniai ir jų panaudojimas gydant ligas, pagrįstas mcp-1, cxcr1 ir p40 raiška
JP5578490B2 (ja) 2008-12-26 2014-08-27 味の素株式会社 ピラゾロピリミジン化合物
EP2518072A4 (en) 2009-12-24 2014-06-04 Ajinomoto Kk IMIDAZOPYRIDAZINE COMPOUNDS
AU2011282215B2 (en) 2010-07-20 2015-04-16 Vestaron Corporation Insecticidal triazines and pyrimidines
CN105963300B (zh) * 2015-03-13 2019-06-11 中国人民解放军军事医学科学院放射与辐射医学研究所 PIKfyve抑制剂抗辐射损伤的用途
CN106279041A (zh) * 2016-08-16 2017-01-04 四川思睿博生物科技有限公司 苯基嘧啶衍生物及其制备方法和用途
BR112020016256A2 (pt) 2018-02-21 2020-12-15 AI Therapeutics, Inc. Terapia de combinação com apilimod e agentes gluta-matérgicos
WO2023118896A1 (en) 2021-12-23 2023-06-29 Subintro Limited Novel antiviral compositions comprising oleic acid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6830751B1 (en) 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
JP3989175B2 (ja) * 1999-04-15 2007-10-10 ブリストル−マイヤーズ スクイブ カンパニー 環状タンパク質チロシンキナーゼ阻害剤
US6384032B1 (en) * 1999-06-17 2002-05-07 Shionogi Bioresearch Corp. Inhibitors of IL-12 production
WO2001047897A1 (en) * 1999-12-28 2001-07-05 Pharmacopeia, Inc. Cytokine, especially tnf-alpha, inhibitors
US6525051B2 (en) * 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
US6680315B2 (en) 2000-06-15 2004-01-20 Synta Pharmaceuticals Corp. Triazine compounds
IL162189A0 (en) 2001-11-30 2005-11-20 Synta Pharmaceuticals Corp Pyrimidine compounds
US6693097B2 (en) 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
CA2545259A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Heteroaryl-hydrazone compounds

Also Published As

Publication number Publication date
EP1458687A2 (en) 2004-09-22
US6958332B2 (en) 2005-10-25
MXPA04005181A (es) 2005-06-17
AU2002357033B2 (en) 2009-05-07
IS7287A (is) 2004-05-26
JP2005519034A (ja) 2005-06-30
US20040053937A1 (en) 2004-03-18
KR100950122B1 (ko) 2010-03-30
NO328144B1 (no) 2009-12-14
WO2003047516A2 (en) 2003-06-12
RU2004119853A (ru) 2006-01-10
EP1458687A4 (en) 2005-03-23
US20060030560A1 (en) 2006-02-09
CA2468349A1 (en) 2003-06-12
IL162189A0 (en) 2005-11-20
EP1458687B1 (en) 2012-01-11
TW200400190A (en) 2004-01-01
RU2320658C2 (ru) 2008-03-27
CN1599726A (zh) 2005-03-23
NO20042742L (no) 2004-08-24
BR0214809A (pt) 2004-09-14
CN100349876C (zh) 2007-11-21
WO2003047516A3 (en) 2003-07-31
AU2002357033A1 (en) 2003-06-17
US7470681B2 (en) 2008-12-30
NZ533437A (en) 2007-05-31
KR20050058257A (ko) 2005-06-16

Similar Documents

Publication Publication Date Title
TWI256953B (en) Pyrimidine compounds
ATE540933T1 (de) Pyrimidinverbindungen als interleukin-12 (il-12) inhibitoren
MEP22608A (en) Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors
CA2398159A1 (en) Sulphonylaminocarbonyltriazolinones having substitutents bonded via oxygen
MY108800A (en) 5-aryl isoxazole derivatives, compositions containing them, process for their preparation and their use as herbicides
NO930189D0 (no) Tioeterkonjugat
DE122006000027I2 (de) Aminderivate
CY1106969T1 (el) Αναστολεις dpp-iv
IL111245A (en) Cyclic amides and fungicidal compositions containing them
DE69328975T2 (de) Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten
HK1001055A1 (en) 5,6-disubstituted-3-pyridylmethyl ammonium halide compounds useful for the preparation of 5-(substituted methyl)-2,3-pyridinedicarboxylic acids
DK0766696T3 (da) Thiazolidinderivater, fremstilling af disse forbindelser og lægemidler indeholdende disse forbindelser
FI922341A0 (fi) Piperidin- och pyrrolidinderivat.
DE69314911D1 (de) Cis-epoxide Derivate, verwendbar als irreversible HIV-Protease Inhibitoren und Verfahren und Zwischenprodukte zu ihrer Herstellung
JO2307B1 (en) Papermidine derivatives
MX9701569A (es) Pirimidin(tio)onas substituidas.
WO2002098853A3 (en) Inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction
DE50110497D1 (de) Schnell härtbare mischungen und kits aus polyfunktionellen cyanaten und aminen, daraus herstellbare duromere und herstellungsverfahren hierfür
DE60237652D1 (de) Variolinderivate und ihre Verwendung als Cytostatika
WO2003014094A3 (de) Heterocyclylarylsulfonamide
DK284380A (da) Fremgangsmaade til fr&mstilling af substituerede 5-( (7-chlor-4-quinolinyl) amino)-3-(aminomethyl)-(1,1!-biphenyl)-2-ol-forbindelser
XIA et al. The constituents of the essential oil from Solidago Canadensis
MX9703150A (es) Derivados de heterociclilamino y heterocicliloxi-cicloalquenilo y su uso como agentes de control de pestes y fungicidas.
MXPA06000383A (es) Pirimidinas 2-sustituidas.
BR8504039A (pt) Composto,processo para sua preparacao,composicoes praguicidas,aplicacao e processo para combater insetos

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees